At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SXTPW 60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant
Trading 11-14 11:46:12 EST
0.0130
+0.0000
0.00%
High0.0130Low0.0130Vol870.00
Open0.0130D1 Closing0.0130Amplitude0.00%
Mkt Cap0.00Tradable Cap0.00Total Shares0.00
T/O13.27T/O Rate--Tradable Shares0.00
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced at-the-Market Under Nasdaq Rules
THOMSON REUTERS  ·  09-06
60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced at-the-Market Under Nasdaq Rules
60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced at-the-Market Under Nasdaq Rules
THOMSON REUTERS  ·  09-04
60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced at-the-Market Under Nasdaq Rules
60 Degrees Pharmaceuticals, Inc. Regains Compliance With Nasdaq Listing Requirements
THOMSON REUTERS  ·  08-29
60 Degrees Pharmaceuticals, Inc. Regains Compliance With Nasdaq Listing Requirements
60 Degrees Pharmaceuticals Second Quarter 2024 Earnings: Misses Expectations
Simply Wall St.  ·  08-17
60 Degrees Pharmaceuticals Second Quarter 2024 Earnings: Misses Expectations
60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q2 Loss, Tops Revenue Estimates
Zacks  ·  08-15
60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q2 Loss, Tops Revenue Estimates
60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results
THOMSON REUTERS  ·  08-14
60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results
Should You Add 60 Degrees Pharmaceuticals, Inc. (SXTP) to Your Stock Portfolio Right Now?
Insider Monkey  ·  08-13
Should You Add 60 Degrees Pharmaceuticals, Inc. (SXTP) to Your Stock Portfolio Right Now?
60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split
THOMSON REUTERS  ·  08-06
60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split
60 DEGREES PHARMACEUTICALS SIGNS CLINICAL TRIAL AGREEMENTS WITH ALL PLANNED TRIAL SITES FOR TAFENOQUINE BABESIOSIS STUDY
THOMSON REUTERS  ·  07-19
60 DEGREES PHARMACEUTICALS SIGNS CLINICAL TRIAL AGREEMENTS WITH ALL PLANNED TRIAL SITES FOR TAFENOQUINE BABESIOSIS STUDY
60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment
GlobeNewswire  ·  07-09
60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment
First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
THOMSON REUTERS  ·  06-27
First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
GlobeNewswire  ·  06-27
First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients With Acute Babesiosis
THOMSON REUTERS  ·  06-11
60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients With Acute Babesiosis
60 Degrees Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
Simply Wall St.  ·  04-03
60 Degrees Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Introduction

Company Name.
60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--